B001

Phase 1Biologic

SShanghai Pharmaceuticals Holding Co., Ltd

B001 is one of 70 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Neuromyelitis OpticaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Neuromyelitis OpticaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Tafasitamab

Incyte

Preclinical

7 6

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

PEG-Intron

Merck & Co.

Preclinical

1 10

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2/3Recruiting

Neuromyelitis Optica

NCT06413654

Clinical

Trials by Indication[1]

Neuromyelitis Optica1 trial

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06413654·132 enrolled

Lymphoma1 trial

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

Completed·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT03332121·30 enrolled

NMOSD1 trial

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 1·NCT05145361·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for B001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — B001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for B001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceuticals Holding Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SShanghai Pharmaceuticals Holding Co., Ltd

B001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Neuromyelitis Optica1 trial

Lymphoma1 trial

NMOSD1 trial

References

Drug Info

Quick Facts

Related News